BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 15, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Abraxane paclitaxel: Preliminary Phase I/II data

Data from an open-label Phase I/II trial in 67 patients showed that Abraxane plus gemcitabine produced complete responses in 5% of patients, partial responses in 39% and stable disease for >=16 weeks in 26%. Median survival was 10.3 months....

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >